-
公开(公告)号：US20180235961A1
公开(公告)日：2018-08-23
申请号：US15752130
申请日：2016-08-12
发明人： Luc De Waal , Matthew Meyerson , Heidi Greulich , Monica Schenone , Alex Burgin , Xiaoyun Wu , Ulrike Sack
IPC分类号： A61K31/50 , A61K9/00 , A61P35/00 , G01N33/574
CPC分类号： A61K31/50 , A61K9/0019 , A61K9/0053 , A61K31/519 , A61K2300/00 , A61P35/00 , G01N33/57488 , G01N2333/916 , G01N2800/52
摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
-
公开(公告)号：US11142522B2
公开(公告)日：2021-10-12
申请号：US16480498
申请日：2018-02-01
申请人： THE BROAD INSTITUTE, INC. , DANA-FARBER CANCER INSTITUTE, INC. , BAYER AKTIENGESELLSCHAFT , BAYER PHARMA AKTIENGESELLSCHAFT
发明人： Timothy A. Lewis , Xiaoyun Wu , Heidi Greulich , Matthew Meyerson , Manuel Ellermann , Philip Lienau , Knut Eis , Antje Margret Wengner , Charlotte Christine Kopitz , Martin Lange
IPC分类号： C07D413/10 , A61P35/02
摘要： The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.
-
3.发明授权公开(公告)号：US12053476B2
公开(公告)日：2024-08-06
申请号：US17161612
申请日：2021-01-28
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , THE BROAD INSTITUTE, INC. , DANA-FARBER CANCER INSTITUTE, INC.
发明人： Timothy A. Lewis , Alex Burgin , Monica Schenone , Xiaoyun Wu , Heidi Greulich , Matthew Meyerson , Luc De Waal , Antje Margret Wengner , Knut Eis , Philip Lienau , Ulrike Sack , Martin Lange
IPC分类号： A61K31/5377 , A61K31/50 , A61P35/00 , C07D413/10
CPC分类号： A61K31/5377 , A61K31/50 , A61P35/00 , C07D413/10
摘要： The present invention features improved compounds, especially
methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).-
公开(公告)号：US11773070B2
公开(公告)日：2023-10-03
申请号：US17865236
申请日：2022-07-14
申请人： Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft , The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc.
发明人： Manuel Ellermann , Stefan Nikolaus Gradl , Charlotte Christine Kopitz , Martin Lange , Adrian Tersteegen , Philip Lienau , Christa Hegele-Hartung , Detlev Sülzle , Timothy A. Lewis , Heidi Greulich , Xiaoyun Wu , Matthew Meyerson , Alex Burgin
IPC分类号： C07D273/04 , C07D413/10 , C07D413/12 , C07D417/10 , C07D471/04 , C07D491/107 , C07D495/10
CPC分类号： C07D273/04 , C07D413/10 , C07D413/12 , C07D417/10 , C07D471/04 , C07D491/107 , C07D495/10
摘要： The present invention provides dihydrooxydiazinone compounds of general formula (I)
in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.-
公开(公告)号：US11207320B2
公开(公告)日：2021-12-28
申请号：US15752130
申请日：2016-08-12
申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , Bayer Pharma Aktiengesellschaft
发明人： Luc De Waal , Matthew Meyerson , Heidi Greulich , Monica Schenone , Alex Burgin , Xiaoyun Wu , Ulrike Sack
IPC分类号： A61K31/50 , G01N33/574 , A61P35/00 , A61K9/00 , A61K31/519
摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
-
6.发明申请公开(公告)号：US20200247783A1
公开(公告)日：2020-08-06
申请号：US16635513
申请日：2018-08-02
申请人： Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft , The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc.
发明人： Manuel Ellermann , Stefan Nikolaus Gradl , Charlotte Christine Kopitz , Martin Lange , Adrian Tersteegen , Philip Lienau , Detlev Sülzle , Timothy Lewis , Heidi Greulich , Xiaoyun Wu , Matthew Meyerson
IPC分类号： C07D403/10 , C07D405/10 , C07D401/10 , C07D237/04 , C07D413/10 , A61P35/04
摘要： The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):
-
公开(公告)号：US20200369633A1
公开(公告)日：2020-11-26
申请号：US16635504
申请日：2018-08-02
申请人： Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft , The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc.
发明人： Manuel Ellermann , Stefan Nikolaus Gradl , Charlotte Christine Kopitz , Martin Lange , Adrian Tersteegen , Philip Lienau , Christa Hegele-Hartung , Detlev Sülzle , Timothy A. Lewis , Heidi Greulich , Xiaoyun Wu , Matthew Meyerson , Alex Burgin
IPC分类号： C07D273/04 , C07D413/10 , C07D413/12 , C07D417/10 , C07D491/107 , C07D495/10 , C07D471/04
摘要： The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US20220071995A1
公开(公告)日：2022-03-10
申请号：US17530402
申请日：2021-11-18
申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , Bayer Pharma Aktiengesellschaft
发明人： Luc De Waal , Matthew Meyerson , Heidi Greulich , Monica Schenone , Alex Burgin , Xiaoyun Wu , Ulrike Sack
IPC分类号： A61K31/50 , G01N33/574 , A61P35/00 , A61K9/00 , A61K31/519
摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
-
公开(公告)号：US11427553B2
公开(公告)日：2022-08-30
申请号：US16635504
申请日：2018-08-02
申请人： Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft , The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc.
发明人： Manuel Ellermann , Stefan Nikolaus Gradl , Charlotte Christine Kopitz , Martin Lange , Adrian Tersteegen , Philip Lienau , Christa Hegele-Hartung , Detlev Sülzle , Timothy A. Lewis , Heidi Greulich , Xiaoyun Wu , Matthew Meyerson , Alex Burgin
IPC分类号： C07D273/04 , C07D413/10 , C07D413/12 , C07D417/10 , C07D471/04 , C07D491/107 , C07D495/10
摘要： The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
-
10.发明授权公开(公告)号：US10966986B2
公开(公告)日：2021-04-06
申请号：US16075077
申请日：2017-02-03
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , THE BROAD INSTITUTE, INC. , DANA-FARBER CANCER INSTITUTE, INC.
发明人： Timothy A. Lewis , Alex Burgin , Monica Schenone , Xiaoyun Wu , Heidi Greulich , Matthew Meyerson , Luc De Waal , Antje Margret Wengner , Knut Eis , Philip Lienau , Ulrike Sack , Martin Lange
IPC分类号： A61K31/5377 , A61K31/50 , C07D413/10 , A61P35/00
摘要： The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.06 秒)
